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Background: Avascular necrosis (AVN) is a debilitating
complication of allogeneic hematopoietic cell trans-
plantation (alloHCT).
Methods: A retrospective review of 845 consecutive patients
 17 years of age who underwent alloHCT at Princess Mar-
garet Cancer Centre from 2002 to 2013 was conducted to
determine the incidence and risk factors for AVN. Univariate
and multivariate analyses were conducted using EZR using
cumulative incidence method considering competing risk.
Results: 48 cases of AVN were identiﬁed. Median follow up
duration among survivors was 3.4 years. Frequent locations
of AVN were: hip (n¼37), shoulder (n¼13), knee (n¼13),
ankle (n¼2), wrist (n¼1), and elbow (n¼1).
Incidence of AVNwas 6.3% (95% CI 4.6-8.5%) and 8.9% (6.5-
11.8%)at4and8years respectively.Risk factoranalysis revealed
the following were signiﬁcantly associated with higher risk of
AVN in a univariate analysis: age< 45 years (p¼0.0039), grade
3-4 acute GVHD (vs grade 0-2; p¼0.054), development of
chronic GVHD (vs no chronic GVHD; p¼0.000016), reduced
intensity conditioning (vs myeloablative; p¼0.017) and a
diagnosis of acute leukemia (vs others; p¼0.045). Multivariate
analysis conﬁrmed two risk factors: 1) younger age (45
years), 9.0% vs 4.4% (p¼0.011, hazard ratio [HR] 2.134, 95% CIFigure 1. Incidence of avascular necrosis according to the risk score based on
the development of chronic GVHD and age (45 years old or younger).[1.186-3.843]) and2) chronicGVHDdevelopment,10.2%vs1.4%
(p¼0.0002, HR 5.762, 95% CI [2.289-14.510]).
Incidence of AVN was 15.7% in patients with moderate to
severe grade chronic GVHD and 3.6% in those with mild
grade GVHD (p¼0.00015).
A risk score model was generated assigning 1 score to
each risk factor and summing the score thus dividing into
three groups: low (score 0, n¼349, 41.3%), intermediate
(score 1, n¼379, 44.9%) and high risk (score 2; n¼116, 13.7%)
(Figure 1). This risk score could stratify the patients accord-
ing to AVN risk (p¼2.49x10-10). The risk of AVN was 1.5%
(0.5-3.6%) in low, 6.2% (3.7-9.5%) in intermediate and 20.8%
(13.0-29.9%) in high risk group.
Conclusions: Moderate/severe grade of chronic GVHD and
younger age (45 years old) are key risk factors for AVN
following allogeneic HCT.8
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Allogeneic hematopoietic cell transplantation (HCT) is the only
potentially curative treatment for patients with chronic mye-
lomonocytic leukemia (CMML), however there little data
regarding prognostic factors and transplant outcomes.
Recently a CMML-speciﬁc prognostic scoring system (CPSS)
was validated in the non-transplant setting [1]. We sought to
validate this scoring system in the HCT setting. We identiﬁed
209 adult patients undergoing HCT for CMML reported to the
Center for International Blood and Marrow Transplant
Research (CIBMTR) from2001 through2012.Themedianageat
transplant was 57 years (range 23-74), with a majority being
male (70%).MosthadKarnofsky Performance Score of 90-100%
(61%). Eighty eight (42%) patients had low/intermediate-1,
while 79 (38%) had intermediate-2/high, and 42 (20%) had
missing CPSS scores. Based on CPSS deﬁnition, 50% had favor-
able, 19% had intermediate, 17% had poor risk, and cytogenetic
data were missing for 14%. Median time from diagnosis to
transplant was 8 months (range 2-170). HCT were performed
with HLA identical siblings (35%), matched unrelated donors
(45%), partially matched unrelated donors (15%), or mis-
matched/indeterminate matched unrelated donors (4%). Pa-
tients received bone marrow (16%) or peripheral blood (84%).
Patients received myeloablative (51%), reduced-intensity
(41%), non-myeloablative (< 5%) or other (<4%) conditioning
regimens. GVHD prophylaxis was cyclosporine-based (37%),
FK-506-based (61%), methotrexate alone (<1%) or missing
(<1%). Median follow up was 51 months (range of 3-122). On
multivariate analyses, CPSS scores, KPS, and graft source were
signiﬁcant predictors of overall survival (p¼0.004, p¼0.01,
p¼0.01 respectively; CPSS and OS ﬁgure below). Higher CPSS
scores were not associated with disease free survival (DFS),
Figure.
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p¼0.08, respectively). To investigate why higher CPSS scores
were associated with higher mortality, we performed analysis
restricted to patients with relapse following HCT. Those with
intermediate-2/high riskhadnearly two-fold increase in riskof
death after relapse compared to thosewith low/intermediate-
1 CPSS scores. Corresponding rates for low/intermediate-1 risk
groups,OSat1year, 3years, and5yearswere61%,48%, and44%
respectivelyand for intermediate-2/high riskgroupswere 38%,
32%, and19%respectively.OSofpatientswho receivedpre-HCT
treatment with hypomethylating agents, chemotherapy, or
both was not different compared to those who received no
therapy prior (p¼0.96).
In summary, CPSS scores, lower KPS scores, and bone
marrow as graft source were associated with poorer out-
comes following HCT.
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Introduction: A donor Killer Cell Ig-like Receptor (KIR) B-
Haplotye has been reported to beneﬁcially inﬂuence
outcome of unrelated transplantation for patients with acute
myeloid leukemia (AML) if the recipient HLA-C phenotype
exhibits a C1 ligand. We validated this association in an in-
dependent cohort of German patients.
Materials and Methods: Patients treated with ﬁrst unrelated
transplantation between 2000 and 2009 for a malignant
hematological disease were included (n¼1694, myeloid dis-
ease n¼982e58.0%, lymphatic diseases n¼712 e 42.0%). Graft
sources were bone marrow (n¼132 e 7.8%) or peripheral
blood stem cells (n¼1562e92.2%). All patients and donors
were high resolution typed for the loci HLA-A,B,C,DRB1,DQB1.
Retrospectively, the donors were typed for KIR genes using a
commercial SSP kit (Invitrogen) and classiﬁed for KIR-AA or
KIR-Bx haplotypes based upon the presence of one or more of
the following activating KIR-receptors: 2DL2, 2DL5, 3DS1,
2DS1, 2DS2, 2DS3, 2DS5. The resulting groups were compared
for the endpoints: relapse, transplant-relatedmortality (TRM),
and overall survival (OS) using competing risks analysis and
extended Cox regression modelling for the subsets myeloid
and lymphatic diseases. Heterogeneity of diagnosis within
each subset was adjusted using stratiﬁcation.
Results: For lymphatic diseases no signiﬁcant difference was
found between the corresponding groups regarding relapse,
OS and TRM. For myeloid diseases however, a signiﬁcantly
lower rate of relapse was found if the donor had a KIR Bx
haplotype and the patient had a C1 HLA-C ligand (5 year
relapse rate 36.2% vs 28.2%, p¼0.012). OS and TRM was
slightly favorable for this group, but no signiﬁcant differ-
ences could be found (OS: 42.2% vs. 37.9%, p¼0.146; TRM:
20.8% vs. 22.9% p¼0.433). The effect on relapse was inde-
pendent of the HLA-matching status, and a relative risk rate
of 0.73 (CI 0.57-0.92, p¼0.009) for the incidence of relapse
was found in multivariate competing risks regression after
correction for the number of HLA mismatches.
Conclusion: A substantially reduced relapse ratewas found in
our analysis for patients with myeloid diseases and the pres-
ence of an HLA-C1 ligand if their donor had a KIR-Bx Haplo-
type. Most patients being transplanted fall in this patient
group. Approximately two thirds of all donors have a KIR-Bx
haplotype. For patients with myeloid diseases and an HLA-C1
ligand, donor KIR typing should be performed if more than
one well matched donors are available. Donors with KIR-AA
haplotypes should be avoided for these patients if possible.10
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